- cafead   Sep 06, 2024 at 11:32: AM
via ImmunityBio has launched a round of layoffs amid potentially troubled financial waters. The staffing cuts come just months after the firm scored FDA approval of its first product, Anktiva (nogapendekin alfa inbakicept-pmln), to be used in combination with Bacillus Calmette-Guérin (BCG) to treat non-muscle invasive bladder cancer (NMIBC).
article source
article source